Trial Profile
A study investigating effect of crizotinib and association between ALK rearrangements and clinical outcomes in primary lung adenocarcinoma patients from China
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Oct 2015
Price :
$35
*
At a glance
- Drugs Crizotinib (Primary)
- Indications Adenocarcinoma; Lung disorders; Non-small cell lung cancer
- Focus Therapeutic Use
- 09 Sep 2015 Results presented at the 16th World Conference on Lung Cancer.
- 21 Jul 2015 New trial record
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.